News

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...
Zacks Investment Research on MSN1d
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...
Crain's Chicago Business2d
AbbVie cancer drug misses the mark in trial for new use
The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...
MPR1d
Venetoclax Plus Azacitidine Misses in Treatment-Naïve, Higher-Risk MDS
The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.
Stocktwits on MSN2d
AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence
AbbVie (ABBV) said on Monday that its late-stage trial evaluating its drug Venetoclax in combination with Azacitidine in the ...
AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment
AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The drugmaker ...
AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint
AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...
Fierce Pharma2d
Roche, AbbVie say trial of Venclexta in patients with myelodysplastic syndromes falls short
Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...
Nasdaq2d
AbbVie's Phase 3 VERONA Study Of Venetoclax Plus Azacitidine In Myelodysplastic Syndrome Fails
(RTTNews) - AbbVie Inc. (ABBV) Monday said its Phase 3 VERONA study evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome ...
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...
Morningstar3d
AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment
AbbVie said its Phase 3 trial evaluating venetoclax in combination with azacitidine to treat higher-risk myelodysplastic syndrome didn't meet the primary endpoint of overall survival. The ...